Keywords: Pfizer, Vyndaqel, Germany, IQWiG, AMNOG, Neurological degeneration

Germany's IQWiG finds some benefit for Pfizer orphan drug Vyndaqel

Article | 11 April 2012

Print This

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis), a treatment for a rate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in